ITASCA, IL--(Marketwire - July 28, 2008) - AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor system, which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed two new agreements to supply SphygmoCor systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of these contracts is USD $1.6 million, the majority of which will be recognized in the current fiscal year. These orders bring the minimum total value of the pharmaceutical trial contracts secured by AtCor over the past 60 days to over US $2.8 million.
